Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenqiang Fan

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Cell Stem Cell|October 4, 2020
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus EpitheliumFadi Jacob, Sarshan R Pather, Wei-Kai Huang, et al.
Signal Transduction and Targeted Therapy|November 25, 2025
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trialJiuliang Zhao, Changsong Lin, Qibing Xie, et al.
Scientific Data|February 7, 2025
A Comprehensive Dataset on Microbiome Dynamics in Rheumatoid Arthritis from a Large-Scale Cohort StudyJing Li, Jun Xu, Jiayang Jin, et al.
Cell|March 5, 2019
Quiescence Modulates Stem Cell Maintenance and Regenerative Capacity in the Aging BrainGeorgios Kalamakis, Daniel Brüne, Srikanth Ravichandran, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 26, 2026
Rapid subunit-level multi-attribute monitoring of succinimide and other PTMs for enhanced quality control of therapeutics antibodiesJin Xu, Chenjing Xu, Gang Wu, et al.
Nature Communications|April 21, 2026
Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trialXia Zhang, Ruiling Feng, Yifan Wang, et al.
BMC Medicine|December 8, 2025
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trialYue Cheng, Honghu Tang, Yufeng Qing, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 17, 2025
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled StudyShangzhu Zhang, Dong Xu, Shengyun Liu, et al.
Lupus Science & Medicine|November 9, 2022
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world studyMiao Shao, Miao Miao, Xia Zhang, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Cell Stem Cell|October 4, 2020
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus EpitheliumFadi Jacob, Sarshan R Pather, Wei-Kai Huang, et al.
Signal Transduction and Targeted Therapy|November 25, 2025
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trialJiuliang Zhao, Changsong Lin, Qibing Xie, et al.
Scientific Data|February 7, 2025
A Comprehensive Dataset on Microbiome Dynamics in Rheumatoid Arthritis from a Large-Scale Cohort StudyJing Li, Jun Xu, Jiayang Jin, et al.
Cell|March 5, 2019
Quiescence Modulates Stem Cell Maintenance and Regenerative Capacity in the Aging BrainGeorgios Kalamakis, Daniel Brüne, Srikanth Ravichandran, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 26, 2026
Rapid subunit-level multi-attribute monitoring of succinimide and other PTMs for enhanced quality control of therapeutics antibodiesJin Xu, Chenjing Xu, Gang Wu, et al.
Nature Communications|April 21, 2026
Low dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trialXia Zhang, Ruiling Feng, Yifan Wang, et al.
BMC Medicine|December 8, 2025
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trialYue Cheng, Honghu Tang, Yufeng Qing, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 17, 2025
Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled StudyShangzhu Zhang, Dong Xu, Shengyun Liu, et al.
Lupus Science & Medicine|November 9, 2022
Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world studyMiao Shao, Miao Miao, Xia Zhang, et al.
Pageof 7